Clinical Trial Update: Korean Post-marketing Surveillance for Xeljanz

View source ↗

Summary

Korean post-marketing surveillance study for Xeljanz (tofacitinib) has completed and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis, Psoriatic Arthritis | Status: COMPLETED | Results posted: 2024-08-27